Safety and Efficacy of an Attenuated Vaccine against Severe Rotavirus Gastroenteritis

10.1097/01.inf.0000142463.72442.91

10.1097/01.inf.0000142464.83628.8e

10.1097/01.inf.0000142465.25992.c3

10.1097/00006454-200107000-00009

10.1590/S1020-49892004001200002

10.3201/eid0905.020562

2003, Wkly Epidemiol Rec, 78, 2

1997, Wkly Epidemiol Rec, 72, 35

1999, MMWR Morb Mortal Wkly Rep, 48, 577

1999, MMWR Morb Mortal Wkly Rep, 48, 1007

10.1016/j.vaccine.2004.01.044

10.1016/S0264-410X(97)00210-7

10.1016/S0140-6736(98)12106-2

10.1086/344732

10.1097/01.inf.0000141722.10130.50

10.1097/01.inf.0000178294.13954.a1

10.1097/01.inf.0000142370.16514.4a

10.1016/j.vaccine.2003.09.016

10.1016/S0022-3476(97)70076-3

10.3109/00365549009027046

10.3201/eid1006.030519

Griffin DD, 2000, J Clin Microbiol, 38, 2784, 10.1128/JCM.38.7.2784-2787.2000

10.1542/peds.2004-0860

10.1016/S1386-6532(98)00013-4

10.1002/sim.4780040211

10.1002/sim.1683

10.1590/S1020-49892000001000002

Lucero Y, 2004, Rev Med Chil, 132, 565, 10.4067/S0034-98872004000500005

10.1097/01.inf.0000078374.82903.e8

10.1097/01.inf.0000055064.76457.f3

10.1097/00006454-200404000-00020

10.1056/NEJM200102223440804

10.1097/00006454-200104000-00008

10.1086/367895

10.1542/peds.110.6.e67

Heaton PM. Overview: characteristics of the investigational pentavalent human-bovine reassortant rotavirus vaccine (PRV): primary efficacy and safety results of the large-scale Rotavirus Efficacy and Safety Trial (REST). Presented at the meeting of the Advisory Committee on Immunization Practices, Atlanta, February 10–11, 2005.

10.1097/01.inf.0000142467.50724.de

10.1056/NEJM199710233371701

10.1056/NEJM199610033351404

10.1016/S0140-6736(04)17664-2

10.1086/431512

10.1002/rmv.448